# DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers

> **NCT07707895** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 60 (estimated)

## Conditions studied

- Small Cell Lung Cancer
- Large Cell Neuroendocrine Lung Carcinoma
- Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology
- Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology

## Interventions

- **DRUG:** Obrixtamig
- **DRUG:** ZL-1310
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT07707895
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-19
- **Primary completion:** 2030-04-26
- **Final completion:** 2030-04-26
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07707895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07707895, "DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07707895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*